Navigation Links
Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
Date:11/5/2013

New York, NY (PRWEB) November 05, 2013

Johnson & Johnson has agreed to pay $2.2 billion to settle charges with the U.S. Department of Justice (DOJ) over the alleged illegal marketing of Risperdal, Invega and Natrecor, Alonso Krangle LLP reports. In a press release issued today, the DOJ called the pact one of the largest ever reached to settle allegations of healthcare fraud.
(justice.gov/opa/pr/2013/November/13-ag-1170.html, DOJ, November 4, 2013)

According to the DOJ’s press release, the charges covered in the settlement announced today include allegations that the company misbranded Risperdal for uses not approved by the U.S. Food & Drug Administration (FDA), including treating elderly patients with dementia and children. Risperdal has never been approved to treat dementia in the elderly, and was only approved for certain pediatric uses in 2006. The DOJ also charged that Johnson & Johnson paid kickbacks to physicians and to Omnicare Inc., the largest pharmacy for nursing homes to drive sales of the antipsychotic drugs, Risperdal and Invega.

“These companies lined their pockets at the expense of the American taxpayers, patients and the private insurance industry,” U.S. Attorney General Eric Holder said during a news conference to announce the settlement. He also asserted that Johnson & Johnson “recklessly put at risk the health of some of the most vulnerable members of our society -- including young children, the elderly, and the disabled,” according to a transcript posted on the DOJ website.
(justice.gov/iso/opa/ag/speeches/2013/ag-speech-131104.html, DOJ November 4, 2013)

Johnson & Johnson is currently facing hundreds of Risperdal lawsuits in a consolidated litigation underway in Pennsylvania Court of Common Pleas in Philadelphia. Many of these lawsuits were filed on behalf of plaintiffs who developed gynecomastia, or male breast growth, allegedly due to their use of Risperdal. In October 2012, Bloomberg News reported that Johnson & Johnson had reached Risperdal settlements in five cases that were designated for the litigation’s first bellwether trials. Among other things, the Risperdal lawsuits alleged that Johnson & Johnson had concealed evidence that Risperdal could cause male breast growth, and that the company had improperly marketed the antipsychotic drug for use in children. (In Re: Risperdal Litigation, Case ID. 100300296)
(bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html)

Alonso Krangle LLP, a law firm focused on fighting for plaintiffs in Risperdal lawsuits, is offering free case reviews to anyone who may have developed gynecomastia due to their use of Risperdal. The Firm’s attorneys have extensive experience litigating cases involving drug injuries, and are currently offering free legal evaluations to alleged victims of Risperdal side effects. Individuals who wish to discuss a potential Risperdal gynecomastia lawsuit are urged to contact Alonso Krangle LLP by calling 1-800-403-6191 or visit the firm’s website, http://www.FightForVictims.com.

About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A highly experienced law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City and New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

Contact:
Alonso Krangle LLP
445 Broad Hollow Road
Suite 205
Melville, New York 11747
Toll-FREE 1-800-403-6191
Tel: 516-350-5555
Fax: 516-350-5554

Read the full story at http://www.prweb.com/releases/2013/11/prweb11302318.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
2. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
3. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
4. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. Nexium MDL Consolidated for Bone Fracture Lawsuits: AttorneyOne Informs
7. Actos Bladder Cancer Lawsuits: Next Status Conference in Federal Actos Litigation Scheduled for January 24, 2013, Bernstein Liebhard LLP Reports
8. DePuy Pinnacle Lawsuits: Explant Preservation Order Issued in Federal DePuy Pinnacle Hip Litigation
9. Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
10. Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
11. Drug Center Adds News on Mirena Lawsuits: Bayer Fighting Move to Federal Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
Breaking Medicine Technology: